modelC09CA04

Diagram of C09CA04

Extends from Pharmacokinetic.Models.PK_2C_enteral.

Information

name:Irbesartan
ATC code:C09CA04
route:oral
compartments:2
dosage:150mg
volume of distribution:53L
clearance:3.0L/h
other parameters in model implementation

Irbesartan is an angiotensin II receptor blocker (ARB) used for the treatment of hypertension and diabetic nephropathy in type 2 diabetes. It is approved and currently used in clinical practice as an oral antihypertensive agent, typically as monotherapy or in combination with other antihypertensive drugs.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers after single oral dose.

References

  1. Marino, MR, & Vachharajani, NN (2002). Pharmacokinetics of irbesartan are not altered in special populations. Journal of cardiovascular pharmacology 40(1) 112–122. DOI:10.1097/00005344-200207000-00014 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12072584

  2. Karatza, E, & Karalis, V (2020). Delay differential equations for the description of Irbesartan pharmacokinetics: A population approach to model absorption complexities leading to dual peaks. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 153 105498–None. DOI:10.1016/j.ejps.2020.105498 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32736091

  3. Choi, CI, et al., & Lee, SY (2012). CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects. European journal of clinical pharmacology 68(2) 149–154. DOI:10.1007/s00228-011-1098-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21842338

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)